Skip to main content

Table 1 Baseline characteristics of study patients

From: Effectiveness and safety assessment of drospirenone/ethinyl estradiol tablet in treatment of PCOS patients: a single center, prospective, observational study

Variables

n

Endpoint

Mean ± SD

25th

50th

75th

p

Age (years)

140

–

24.65 ± 4.33

22.00

25.00

27.75

–

BMI (kg/m2)

140

Before

22.07 ± 4.09

19.00

21.30

24.75

< 0.001

After

21.35 ± 3.22

18.92

21.18

23.04

WHR

138

Before

0.86 ± 0.07

0.82

0.86

0.90

0.026

After

0.85 ± 0.06

0.81

0.85

0.89

LOV (cm3)

49

Before

11.80 ± 10.66

6.73

9.45

12.78

< 0.001

After

7.46 ± 3.21

5.13

6.98

9.33

ROV (cm3)

48

Before

12.31 ± 10.49

7.71

9.33

12.02

0.001

After

9.02 ± 6.24

5.30

7.72

10.62

  1. BMI body mass index; WHR waist-hip ratio; LOV left ovarian volume; ROV right ovarian volume